Meningitis: Definition Type, and Treatment

Meningitis

Meningitis represents a potentially life-threatening clinical syndrome characterized by inflammation of the protective membranes—known as the meninges—surrounding the brain and spinal cord. It is a condition of considerable global health concern, known to affect individuals of all age groups, with neonates, children, and immunocompromised individuals being the most susceptible. The disease may progress rapidly, and if not diagnosed and treated promptly, it can result in significant morbidity or mortality. The primary pathological feature is the infiltration of the subarachnoid space by inflammatory cells, resulting in increased intracranial pressure, brain edema, and potential neurological deficits.

Meningitis may be caused by a range of infectious agents, including bacteria, viruses, fungi, and parasites, as well as by non-infectious causes such as autoimmune disorders, drugs, and malignancies. This multifaceted etiology leads to varying clinical manifestations, prognosis, and treatment strategies, depending on the causative factor. Timely intervention with appropriate antimicrobial therapy, corticosteroids, and supportive measures is critical to improving outcomes.

2. Definition

Meningitis is defined as the inflammation of the leptomeninges, the membranous coverings of the brain and spinal cord, specifically the pia mater and arachnoid mater. The condition results from infection, autoimmune activity, or other inflammatory processes that trigger a cascade of events leading to cellular infiltration, increased cerebrospinal fluid (CSF) protein levels, and alteration of the blood-brain barrier (BBB).

The disease is broadly classified into acute, subacute, and chronic types based on the duration and progression of symptoms. Acute meningitis typically develops within hours to days, subacute over a week to a month, and chronic over a period of more than four weeks.

3. Epidemiology of Meningitis

3.1 Global Burden

Meningitis remains a global health threat, with an estimated 2.5 million cases and over 250,000 deaths annually, according to the World Health Organization (WHO). The highest burden is observed in the “meningitis belt” of Sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. This region is especially susceptible to epidemic outbreaks of meningococcal meningitis, particularly during the dry season when dust and upper respiratory tract infections predispose individuals to infection.

3.2 Age and Risk Factors

• Neonates and Infants: High vulnerability due to immature immune systems.
• Adolescents and Young Adults: Increased incidence of meningococcal disease.
• Elderly and Immunocompromised: Increased risk of Listeria and fungal meningitis.

Risk factors include:

• Lack of vaccination
• Overcrowding (e.g., dormitories, military barracks)
• Immunosuppression
• Head trauma or neurosurgical procedures
• Congenital defects such as spina bifida

4. Etiology of Meningitis

The causative agents of meningitis are highly diverse and can be broadly categorized into infectious and non-infectious etiologies.

4.1 Infectious Causes

Bacterial Meningitis

Common pathogens include:

• Neonates: Group B Streptococcus, Escherichia coli, Listeria monocytogenes
• Children and Adults: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (Hib)
• Elderly: Listeria monocytogenes
• Post-neurosurgical or trauma: Staphylococcus aureus, Pseudomonas aeruginosa

Viral Meningitis

More benign than bacterial forms. Common viruses:

• Enteroviruses (Coxsackievirus, Echovirus)
• Herpes simplex virus (HSV)
• Varicella zoster virus (VZV)
• Mumps virus
• HIV

Fungal Meningitis

• Cryptococcus neoformans (commonly in immunocompromised, e.g., HIV/AIDS)
• Candida species
• Histoplasma capsulatum
• Coccidioides immitis

Parasitic Meningitis

• Naegleria fowleri: causes primary amoebic meningoencephalitis (PAM)
• Toxoplasma gondii
• Angiostrongylus cantonensis

4.2 Non-Infectious Causes

• Autoimmune diseases (e.g., systemic lupus erythematosus)
• Drug-induced (e.g., NSAIDs, intravenous immunoglobulins)
• Neoplastic meningitis (meningeal carcinomatosis)
• Post-surgical or traumatic causes
• Sarcoidosis

5. Types of Meningitis

Acute Bacterial Meningitis: This is the most severe and rapidly progressing form. It involves pus-forming bacteria and presents with fever, headache, neck stiffness, photophobia, and altered mental status. Lumbar puncture typically reveals elevated WBC count, increased protein, and decreased glucose levels.

Viral (Aseptic) Meningitis: Generally self-limiting and mild. It is diagnosed when clinical features of meningitis are present, but CSF cultures are negative for bacteria. Lymphocytic predominance in CSF is typical, and glucose levels are usually normal.

Chronic Meningitis: Lasts over 4 weeks. Commonly caused by Mycobacterium tuberculosis, Cryptococcus, or neoplastic infiltration. Presents with insidious onset of symptoms including low-grade fever, lethargy, and cranial nerve palsies.

5.4 Fungal Meningitis

More prevalent in immunocompromised patients, especially with HIV/AIDS. Symptoms develop slowly and include headache, fever, and confusion. Diagnosis relies on India ink staining, cryptococcal antigen, and culture.

Parasitic Meningitis: Rare but fatal. Naegleria fowleri, the “brain-eating amoeba,” causes PAM with fulminant progression leading to death within days.

Pathophysiology of Meningitis

Step 1: Entry of Pathogen

The germs that cause meningitis, such as bacteria or viruses, usually enter the body through the nose or throat. From here, they get into the bloodstream. Once in the blood, they are carried to the brain and are able to cross the blood–brain barrier, which normally protects the brain. After crossing, they reach the protective layers of the brain known as the meninges.

Step 2: Multiplication in CSF

When the pathogens enter the cerebrospinal fluid (CSF), they multiply rapidly. This happens because the CSF has very few immune cells and antibodies. In this weak defense environment, germs grow quickly and spread around the brain and spinal cord.

Step 3: Inflammation of the Meninges

The body detects the infection and activates the immune system. White blood cells move into the CSF and meninges to fight the germs. These cells release chemicals called cytokines, which cause inflammation. As a result, the blood vessels in the meninges become swollen and leaky.

Step 4: Brain Swelling (Edema)

The leaky blood vessels allow fluid to escape into the brain tissue. This leads to swelling of the brain, which is called edema. Because the skull is a closed space, this swelling increases the pressure inside the head, also called intracranial pressure.

Step 5: Reduced Blood Flow and Oxygen

The increased pressure inside the skull presses on the brain’s blood vessels. This reduces the amount of blood and oxygen that can reach brain cells. Without enough oxygen and nutrients, brain cells become damaged and may start to die.

Step 6: Symptoms and Effects

The irritation of the meninges causes headache, fever, and neck stiffness, which are classic symptoms of meningitis. The swelling and high pressure inside the skull lead to confusion, vomiting, and sometimes seizures. In severe cases, it can cause coma or even death. Survivors may also face long-term problems such as hearing loss or memory difficulties.

6. Causes of Meningitis

6.1 Pathophysiological Mechanisms

The pathogenesis begins with the invasion of the central nervous system (CNS) via:

• Hematogenous spread (most common)
• Contiguous spread from sinusitis, otitis media
• Direct inoculation through trauma, surgery

This leads to:

1. Activation of host immune response
2. Release of pro-inflammatory cytokines like IL-1, TNF-α
3. Breakdown of the blood-brain barrier
4. Cerebral edema, increased intracranial pressure
5. Reduced cerebral perfusion and possible ischemic injury

7. Clinical Manifestations

Classic Triad

• Fever
• Neck stiffness
• Altered mental status

Other symptoms:

• Headache
• Photophobia
• Vomiting
• Seizures
• Focal neurological signs
• Petechial rash (especially in meningococcal meningitis)

In infants:

• Bulging fontanelle
• Poor feeding
• Hypotonia
• Irritability

8. Diagnosis of Meningitis

8.1 Clinical Evaluation

• History and physical examination
• Kernig’s and Brudzinski’s signs (meningeal irritation)

8.2 Laboratory Tests

• Lumbar puncture (CSF analysis)
  • Opening pressure
  • Cell count and differential
  • Protein and glucose concentration
  • Gram stain and culture
  • PCR for viral DNA
  • Antigen detection tests (e.g., cryptococcal antigen)

8.3 Imaging

• CT or MRI before lumbar puncture in patients with:
  • Papilledema
  • New-onset seizures
  • Altered sensorium
  • Immunocompromised states

9. Treatment of Meningitis

9.1 Empirical Antimicrobial Therapy

Empirical treatment should be initiated immediately after CSF collection:

• Duration:
  • Neisseria meningitidis: 7 days
  • H. influenzae: 7-10 days
  • Streptococcus pneumoniae: 10-14 days
  • Listeria or Gram-negative bacilli: ≥21 days

9.2 Corticosteroids

• Dexamethasone 0.15 mg/kg every 6 hours for 4 days
• Shown to reduce neurological sequelae, particularly in S. pneumoniae meningitis

9.3 Supportive Treatment

• Antipyretics
• Anticonvulsants (if seizures)
• Oxygen and IV fluids
• Intracranial pressure management

9.4 Specific Treatments

• Fungal meningitis: Amphotericin B + Flucytosine followed by Fluconazole
• Tubercular meningitis: HRZE regimen (Isoniazid, Rifampin, Pyrazinamide, Ethambutol) + steroids
• Viral meningitis: Supportive care; Acyclovir for HSV

10. Prevention of Meningitis

Vaccination

• Hib vaccine
• Pneumococcal conjugate vaccine (PCV13, PPSV23)
• Meningococcal vaccines (MenACWY, MenB)
• BCG vaccine for tuberculosis

Prophylaxis

• Close contacts of meningococcal meningitis cases: Rifampin, Ciprofloxacin, or Ceftriaxone
• Hib exposure in unvaccinated children: Rifampin prophylaxis

11. Complications and Prognosis

• Early complications: Seizures, hydrocephalus, cerebral infarction
• Late complications: Hearing loss, cognitive impairment, motor deficits
• Mortality:
  • Bacterial meningitis: 5–30%
  • Viral meningitis: <1%
  • Fungal and tubercular forms: higher in immunocompromised

Conclusion

Meningitis continues to be a major public health challenge due to its rapid onset, high mortality, and potential for permanent neurological damage. A nuanced understanding of the different forms of meningitis, their etiology, and appropriate therapeutic interventions is critical for timely and effective management. Advancements in molecular diagnostics, antimicrobial therapy, and vaccination strategies have significantly improved the prognosis of this devastating disease. Nonetheless, the persistent prevalence in low-resource settings and the emergence of antibiotic resistance call for continued vigilance, public health initiatives, and global collaboration to combat meningitis comprehensively.